https://www.pharmaradar360.com/article/a6d04440b8d67e7bPharmaRadar360en2026-04-11T00:00:00.000ZLatest Researchhttps://www.pharmaradar360.com/article/19f59684ccd74cc6PharmaRadar360en2026-04-11T00:00:00.000ZGeliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commutehttps://www.pharmaradar360.com/article/9b3cae0805a2d71cPharmaRadar360en2026-04-10T22:06:02.000ZAllogene Therapeutics Conference Callhttps://www.pharmaradar360.com/article/1614d815a3d8ad28PharmaRadar360en2026-04-10T21:04:26.000ZAllogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202https://www.pharmaradar360.com/article/98bd3f68fba7139fPharmaRadar360en2026-04-10T20:53:38.000ZPredicting T Cell Recognition: New Insights from Large-Scale Activation Datahttps://www.pharmaradar360.com/article/3c0f8e692dacdbe3PharmaRadar360en2026-04-10T10:00:00.000ZTislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)https://www.pharmaradar360.com/article/4ffded644d4b86c0PharmaRadar360en2026-04-10T07:00:00.000ZA Clínic-IDIBAPS study discovers that nanoparticles with DNA enhance the effect of immunotherapy against cancerhttps://www.pharmaradar360.com/article/4d6a4308a4bc8473PharmaRadar360en2026-04-10T03:15:00.000ZDifferences in cells’ protein factories may help explain human diversityhttps://www.pharmaradar360.com/article/9103b3a1cebe5467PharmaRadar360en2026-04-10T01:30:00.000ZAlexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseaseshttps://www.pharmaradar360.com/article/09ccb62990dfe934PharmaRadar360en2026-04-10T01:00:00.000ZWhy do anglerfish have glowing lures? It might be sexhttps://www.pharmaradar360.com/article/bc4fcba9d4b99077PharmaRadar360en2026-04-10T00:00:00.000ZShionogi Selected as a “DX Stock 2026”https://www.pharmaradar360.com/article/23aacc01a6fc6a7dPharmaRadar360en2026-04-10T00:00:00.000ZOrion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 20264/10/2026 Press releasehttps://www.pharmaradar360.com/article/590fdec1e8e3be5cPharmaRadar360en2026-04-10T00:00:00.000ZCD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapyhttps://www.pharmaradar360.com/article/404d785b59a9a07aPharmaRadar360en2026-04-10T00:00:00.000ZTerminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerhttps://www.pharmaradar360.com/article/7cd148ff1e968ffbPharmaRadar360en2026-04-10T00:00:00.000ZSLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescencehttps://www.pharmaradar360.com/article/85acba16356a96b3PharmaRadar360en2026-04-10T00:00:00.000ZDeepath-SCC: a deep learning model for accurate tissue origin identification in squamous cell carcinomahttps://www.pharmaradar360.com/article/6759d1b0dafb588fPharmaRadar360en2026-04-10T00:00:00.000ZOutcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyhttps://www.pharmaradar360.com/article/84391a5d68d16155PharmaRadar360en2026-04-10T00:00:00.000ZThe role of the molecular tumor board: learnings from the ROME trialhttps://www.pharmaradar360.com/article/d7022620a11be15fPharmaRadar360en2026-04-10T00:00:00.000ZDeep learning-based pathomics signature predicts prognosis and treatment response in gastric cancer: a multicenter retrospective studyhttps://www.pharmaradar360.com/article/40f7e2112f470eb9PharmaRadar360en2026-04-10T00:00:00.000ZIdorsia issues invitation to the 2026 Annual General Meeting of Shareholdershttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-10T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/6c8933a2d3b98a96PharmaRadar360en2026-04-10T00:00:00.000Zstroke visionaries dr erika weilhttps://www.pharmaradar360.com/article/b13297fc24783793PharmaRadar360en2026-04-10T00:00:00.000ZViatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meetinghttps://www.pharmaradar360.com/article/fe73c55896b51a4bPharmaRadar360en2026-04-10T00:00:00.000ZViking Therapeutics to Participate at Upcoming Investor Conferenceshttps://www.pharmaradar360.com/article/43bf7ad07ba58d2fPharmaRadar360en2026-04-10T00:00:00.000ZIDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026https://www.pharmaradar360.com/article/78202b23746b7226PharmaRadar360en2026-04-09T21:17:00.000ZFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.https://www.pharmaradar360.com/article/a8a7c5178c0602f9PharmaRadar360en2026-04-09T20:25:00.000ZEmergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Programhttps://www.pharmaradar360.com/article/318faeabfec65a3fPharmaRadar360en2026-04-09T13:46:04.000ZViz.ai Earns Back-to-Back No. 1 Ranking in Black Book Survey of AI Clinical Decision Support Solutions